Q-omics provides the consensus-scored TOR4A profile across patient tissues and cancer cell-line models. TOR4A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TOR4A is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, TOR4A protein abundance shows 23,997 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRP, and LSCC as cancer lineages where TOR4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TOR4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TOR4A survival associations across molecular data types. TOR4A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TOR4A RNA expression–survival associations across cancer types. High TOR4A expression shows unfavorable associations in ACC, LUAD, LGG, CESC and MESO, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TOR4A RNA expression.
This table summarizes TOR4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TOR4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TOR4A shows lower tumor expression in KICH and LUSC and higher tumor expression in KIRP, HNSC, KIRC and STAD. The KIRP box plot shows higher TOR4A RNA expression in tumor versus normal tissue (log2 FC = +1.511, t-test p < 0.001).
This table shows molecular features associated with TOR4A in patient tissues and cancer cell lines. In patient samples, TOR4A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TOR4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
